BR112015018047A8 - método para preparar composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão e as mesmas - Google Patents
método para preparar composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão e as mesmas Download PDFInfo
- Publication number
- BR112015018047A8 BR112015018047A8 BR112015018047A BR112015018047A BR112015018047A8 BR 112015018047 A8 BR112015018047 A8 BR 112015018047A8 BR 112015018047 A BR112015018047 A BR 112015018047A BR 112015018047 A BR112015018047 A BR 112015018047A BR 112015018047 A8 BR112015018047 A8 BR 112015018047A8
- Authority
- BR
- Brazil
- Prior art keywords
- heparinoid
- buffer
- compositions
- acute
- acting anesthetic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
resumo composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão a presente invenção refere-se a métodos aprimorados para preparar composições que incluem um heparinoide, um anestésico de ação aguda e um tampão. esses métodos resultam em composições em que o heparinoide e o anestésico de ação aguda são pelo menos 90% estáveis por um ano. as composições preparadas por esses métodos e que têm tais propriedades de estabilidade aprimoradas são também descritos, assim como métodos para uso dessas composições para tratar, melhorar ou impedir distúrbios do trato urinário inferior, tal como cistite intersticial. 1/1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361757592P | 2013-01-28 | 2013-01-28 | |
PCT/US2014/013352 WO2014171986A1 (en) | 2013-01-28 | 2014-01-28 | Stable compositions comprising heparinoid, acute-acting anesthetic, and buffer |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015018047A2 BR112015018047A2 (pt) | 2017-07-18 |
BR112015018047A8 true BR112015018047A8 (pt) | 2019-11-05 |
Family
ID=51731742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015018047A BR112015018047A8 (pt) | 2013-01-28 | 2014-01-28 | método para preparar composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão e as mesmas |
Country Status (13)
Country | Link |
---|---|
US (1) | US20150359816A1 (pt) |
EP (1) | EP2948154A4 (pt) |
JP (2) | JP2016517390A (pt) |
KR (1) | KR20160008496A (pt) |
CN (1) | CN105263503A (pt) |
AU (2) | AU2014254472A1 (pt) |
BR (1) | BR112015018047A8 (pt) |
CA (1) | CA2899636C (pt) |
IL (1) | IL240194B (pt) |
MX (1) | MX2015009696A (pt) |
SG (1) | SG11201505853RA (pt) |
WO (1) | WO2014171986A1 (pt) |
ZA (1) | ZA201505814B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10117847B2 (en) | 2015-12-04 | 2018-11-06 | Ventis Pharma | Extended duration local anesthetic formulation |
EP3609483A4 (en) * | 2017-04-12 | 2021-01-20 | Urigen Pharmaceuticals, Inc. | ITEM OF MANUFACTURING CONSISTING OF LOCAL ANESTHETICS, BUFFER AND GLYCOSAMINOGLYCANE IN A SYRINGE OF IMPROVED STABILITY |
ES2775673T3 (es) * | 2017-05-12 | 2020-07-27 | Farco Gmbh | Composición para el tratamiento de enfermedades inflamatorias del tracto urogenital que contiene sulfato de condonita (4,5 mg/ml), ácido hialurónico (16 mg/ml) y tampón de fosfato (pH 6,1 a 7,9) con mayor estabilidad de almacenamiento para tratar la cistitis |
EP3415163B1 (de) * | 2017-06-13 | 2023-02-22 | Farco-Pharma GmbH | Zusammensetzung mit lokalanästhetischer wirkung und deren verwendung |
ES2968164T3 (es) * | 2019-04-26 | 2024-05-08 | Tcm Biotech Int Corp | Composición farmacéutica para la prevención de infección urinaria recurrente |
TW202105790A (zh) * | 2019-05-17 | 2021-02-01 | 日商半導體能源研究所股份有限公司 | 發光元件、發光裝置、電子機器及照明裝置 |
EP3998932A4 (en) * | 2019-07-18 | 2023-08-16 | C. Lowell Parsons | ALKALINIZATION OF THE URINARY BLADDER WALL BEFORE TREATMENT WITH INTRAVESICAL HEPARIN AND ALKALIZED LIDOCAINE TO ENHANCE SYMPTOMS RELIEF OF PAIN BLADDER |
CN115814099B (zh) * | 2022-12-19 | 2024-04-26 | 成都蓉生药业有限责任公司 | 一种人凝血因子ix的干热处理稳定剂及其制剂与制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5603695A (en) * | 1995-06-07 | 1997-02-18 | Erickson; Kim | Device for alkalizing local anesthetic injection medication |
DK1708722T3 (da) * | 2004-01-28 | 2014-08-25 | Univ California | Ny interstitiel terapi til øjeblikkelig symptomlindring og kronisk terapived interstitiel cystit |
AU2006204769A1 (en) * | 2005-01-14 | 2006-07-20 | Urigen, Inc. | Kits and improved compositions for treating lower urinary tract |
WO2007073397A1 (en) * | 2005-12-19 | 2007-06-28 | Urigen, Inc. | Kits and improved compositions for treating lower urinary tract discorders |
US8450475B2 (en) * | 2008-08-04 | 2013-05-28 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
ES2634505T3 (es) * | 2009-08-13 | 2017-09-28 | Lubris Llc | Tratamiento de PRG4 para la cistitis intersticial |
EA201391014A1 (ru) * | 2011-01-06 | 2014-01-30 | С. Лоуэлл Парсонс | Способ производства композиции, содержащей местный анестетик, гепариноид и буфер |
US9486747B2 (en) * | 2014-08-12 | 2016-11-08 | The Curators Of The University Of Missouri | Nanocomposite membranes with advanced antifouling properties under visible light irradiation |
-
2014
- 2014-01-28 CN CN201480018245.5A patent/CN105263503A/zh active Pending
- 2014-01-28 EP EP14785471.5A patent/EP2948154A4/en active Pending
- 2014-01-28 SG SG11201505853RA patent/SG11201505853RA/en unknown
- 2014-01-28 US US14/763,369 patent/US20150359816A1/en active Pending
- 2014-01-28 CA CA2899636A patent/CA2899636C/en active Active
- 2014-01-28 BR BR112015018047A patent/BR112015018047A8/pt not_active Application Discontinuation
- 2014-01-28 JP JP2015555403A patent/JP2016517390A/ja active Pending
- 2014-01-28 WO PCT/US2014/013352 patent/WO2014171986A1/en active Application Filing
- 2014-01-28 AU AU2014254472A patent/AU2014254472A1/en not_active Abandoned
- 2014-01-28 KR KR1020157023381A patent/KR20160008496A/ko not_active Application Discontinuation
- 2014-01-28 MX MX2015009696A patent/MX2015009696A/es unknown
-
2015
- 2015-07-28 IL IL240194A patent/IL240194B/en unknown
- 2015-08-13 ZA ZA2015/05814A patent/ZA201505814B/en unknown
-
2018
- 2018-08-13 JP JP2018152223A patent/JP2019006783A/ja active Pending
- 2018-10-11 AU AU2018247284A patent/AU2018247284A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112015018047A2 (pt) | 2017-07-18 |
AU2018247284A1 (en) | 2018-11-01 |
JP2019006783A (ja) | 2019-01-17 |
JP2016517390A (ja) | 2016-06-16 |
IL240194A0 (en) | 2015-09-24 |
EP2948154A1 (en) | 2015-12-02 |
CN105263503A (zh) | 2016-01-20 |
EP2948154A4 (en) | 2016-09-14 |
AU2014254472A1 (en) | 2015-08-20 |
ZA201505814B (en) | 2016-11-30 |
KR20160008496A (ko) | 2016-01-22 |
SG11201505853RA (en) | 2015-08-28 |
WO2014171986A1 (en) | 2014-10-23 |
CA2899636A1 (en) | 2014-10-23 |
CA2899636C (en) | 2021-05-25 |
IL240194B (en) | 2021-12-01 |
MX2015009696A (es) | 2016-03-31 |
US20150359816A1 (en) | 2015-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015018047A8 (pt) | método para preparar composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão e as mesmas | |
PH12018501226A1 (en) | Methods for treating huntingtons disease | |
AU2018236800B2 (en) | DNA-PK inhibitors | |
MX2018005829A (es) | Composiciones para tratar el cabello. | |
MX2017012512A (es) | Moléculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas. | |
PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
MY184628A (en) | Afucosylated anti-fgfr2iiib antibodies | |
MX2021002406A (es) | Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica. | |
SG10201809290SA (en) | Compositions and Methods to Treating Hemoglobinopathies | |
MX359327B (es) | Composiciones y sus usos para tratar y prevenir la enfermedad de huntington. | |
MD20150062A2 (ro) | Compuşi antivirali | |
MX2015009270A (es) | Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk). | |
MX2015008888A (es) | Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido. | |
BR112017002963A2 (pt) | derivados citotóxicos de benzodiazepina | |
MX2020002544A (es) | Sales de glicopirrolato. | |
MX2015012176A (es) | Metodos de usar zscan4 para rejuvenecer celulas humanas. | |
BR112015029462A2 (pt) | Inibidores de quinase | |
GEP201706760B (en) | Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same | |
CY1121238T1 (el) | Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων | |
BR112018008931A2 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
BR112015020667A2 (pt) | método de preparar inibidores de glucosilceramida sintase | |
RS53457B (en) | COMPOSITION AND ITS APPLICATION IN THE TREATMENT OF ANAL RAGAD | |
WO2014194053A3 (en) | Carbohydrate compounds for nutritional and therapeutic use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |